{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:22:40Z","timestamp":1793020960822,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003248","name":"Ontario Mental Health Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003248","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005877","name":"Luonnontieteiden ja Tekniikan Tutkimuksen Toimikunta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ibroneuroscience.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.neuroscience.2011.09.056","type":"journal-article","created":{"date-parts":[[2011,10,9]],"date-time":"2011-10-09T17:14:35Z","timestamp":1318180475000},"page":"116-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"special_numbering":"C","title":["The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling"],"prefix":"10.1016","volume":"199","author":[{"given":"L.P.","family":"Sutton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Rushlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2011.09.056_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.biopsych.2004.11.036","article-title":"Antipsychotics alter the protein expression levels of \u03b2-catenin and GSK-3 in the rat medial prefrontal cortex and striatum","volume":"57","author":"Alimohamad","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1471-4159.2005.03388.x","article-title":"The effects of antipsychotics on \u03b2-catenin, glycogen synthase kinase-3 and dishevelled in the ventral midbrain of rats","volume":"95","author":"Alimohamad","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib3","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1073\/pnas.0307921101","article-title":"Lithium antagonizes dopamine-dependent behaviors mediated by an AKT\/glycogen synthase kinase 3 signaling cascade","volume":"101","author":"Beaulieu","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01285562","article-title":"The effect of acute and chronic lithium on forskolin-induced reduction of rat activity","volume":"104","author":"Bersudsky","year":"1997","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib5","doi-asserted-by":"crossref","first-page":"35040","DOI":"10.1074\/jbc.M109.047456","article-title":"G protein-coupled receptor kinases phosphorylate LRP6 in the Wnt pathway","volume":"284","author":"Chen","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/378785a0","article-title":"Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B","volume":"378","author":"Cross","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1017\/S1461145709990344","article-title":"Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis","volume":"13","author":"Cruz","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng1296","article-title":"Convergent evidence for impaired AKT1-GSK3\u03b2 signaling in schizophrenia","volume":"36","author":"Emamian","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3590001","article-title":"GSK3 takes centre stage more than 20 years after its discovery","volume":"359","author":"Frame","year":"2001","journal-title":"Biochem J"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib11","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1176\/appi.ajp.2009.08121873","article-title":"Roles of the Akt\/GSK-3 and Wnt signaling pathways in schizophrenia and antipsychotic drug action","volume":"167","author":"Freyberg","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.npp.1300283","article-title":"In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3","volume":"29","author":"Gould","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tibs.2003.12.004","article-title":"The glamour and gloom of glycogen synthase kinase-3","volume":"29","author":"Jope","year":"2004","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib16","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1128\/MCB.19.6.4414","article-title":"DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability","volume":"19","author":"Kishida","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib17","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1073\/pnas.93.16.8455","article-title":"A molecular mechanism for the effect of lithium on development","volume":"93","author":"Klein","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1017\/S1461145705006097","article-title":"Psychotropic drugs affect Ser9-phosphorylated GSK-3\u03b2 protein levels in rodent frontal cortex","volume":"9","author":"Kozlovsky","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.157.5.831","article-title":"Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients","volume":"157","author":"Kozlovsky","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib20","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00702-004-0166-3","article-title":"Reduced GSK-3\u03b2 mRNA levels in postmortem dorsolateral prefrontal cortex of schizophrenic patients","volume":"111","author":"Kozlovsky","year":"2004","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib21","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/sj.npp.1300439","article-title":"In vivo regulation of glycogen synthase kinase-3\u03b2 (GSK3\u03b2) by serotonergic activity in mouse brain","volume":"29","author":"Li","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib22","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cell.2009.03.005","article-title":"DISC1 partners with GSK3\u03b2 in neurogenesis","volume":"136","author":"Ming","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-3806(02)00639-9","article-title":"Glycogen synthase kinase (GSK)-3\u03b2 levels and activity in a neurodevelopmental rat model of schizophrenia","volume":"141","author":"Nadri","year":"2003","journal-title":"Dev Brain Res"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib24","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","article-title":"Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials","volume":"166","author":"Nelson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s000180050449","article-title":"Signaling through beta-catenin and Lef\/Tcf","volume":"56","author":"Novak","year":"1999","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib26","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1523\/JNEUROSCI.4753-03.2004","article-title":"Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium","volume":"24","author":"O'Brien","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881107081521","article-title":"Differential expression of IEG mRNA in rat brain following acute treatment with clozapine or haloperidol: a semi-quantitative RT-PCR study","volume":"22","author":"Robbins","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib28","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0022-3565(25)23800-9","article-title":"Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity","volume":"271","author":"Robertson","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib29","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.biopsych.2004.10.039","article-title":"Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine","volume":"57","author":"Roh","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0197-0186(95)00156-5","article-title":"Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study","volume":"29","author":"Semba","year":"1996","journal-title":"Neurochem Int"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s007020200035","article-title":"Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder","volume":"109","author":"Shaldubina","year":"2002","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-8993(98)00087-0","article-title":"Expression of Fos protein in the limbic regions of the rat following haloperidol decanoate","volume":"791","author":"Sun","year":"1998","journal-title":"Brain Res"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1471-4159.2007.04527.x","article-title":"Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3","volume":"102","author":"Sutton","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib34","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1101\/gad.9.9.1087","article-title":"The dishevelled protein is modified by wingless signaling in Drosophila","volume":"9","author":"Yanagawa","year":"1995","journal-title":"Genes Dev"},{"key":"10.1016\/j.neuroscience.2011.09.056_bib35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nature04185","article-title":"A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation","volume":"438","author":"Zeng","year":"2005","journal-title":"Nature"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452211011420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452211011420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T17:12:01Z","timestamp":1741799521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452211011420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":35,"alternative-id":["S0306452211011420"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2011.09.056","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2011.09.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 IBRO. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}